Results 71 to 80 of about 50,884 (170)

Parenteral iron—Does it increase infection risk?

Vox Sanguinis, Volume 121, Issue 7, Page 914-922, July 2026.
Abstract Background and Objectives Iron deficiency (ID) and iron deficiency anaemia (IDA) are prevalent conditions impacting various patient populations, both surgical and non‐surgical conditions. The advent of patient blood management (PBM) has promoted intravenous (IV) iron therapy as an alternative to oral iron and blood transfusions.
Joyisa Deb, Aswin K. Mohan, Suhasini Sil, Suvro Sankha Datta, Yoghini Nagandran, Manideepa Maji, Mohammad Kamrul Hassan Majumder, Saikat Mandal   +7 more
wiley   +1 more source

Incidence of hypophosphatemia in patients with inflammatory bowel disease treated with ferric carboxymaltose or iron isomaltoside

, 2019
Background: Iron deficiency and iron deficiency anaemia are common complications in inflammatory bowel disease (IBD). In patients with moderate‐to‐severe anaemia, oral iron intolerance or ineffectiveness of oral iron, ferric carboxymaltose and iron ...
Zoller, Heinz, Moum, Bjørn, Jahnsen, Marte Eide, Finnes, Elisabeth, Detlie, Trond Espen, Lindstrøm, Jonas Christoffer, Jahnsen, Jørgen   +6 more
core   +1 more source

Symptomatic severe hypophosphatemia after intravenous ferric carboxymaltose

JGH Open, 2019
Intravenous iron is commonly prescribed for treatment of iron deficiency, with modern formulations demonstrating an acceptable safety profile in the majority of patients.
Wendy Fang, Lawrence P McMahon, Stephen Bloom, Mayur Garg   +3 more
doaj   +1 more source

Administration of Intravenous Iron Formulations Induces Complement Activation in-vivo

Frontiers in Immunology, 2019
Background: Intravenous (IV) iron is widely used to treat anemia in chronic kidney disease patients. Previously, iron formulations were shown to induce immune activation in-vitro. The current study aimed to investigate the effect of IV iron on complement
Bernardo Faria, Bernardo Faria, Bernardo Faria, Mariana Gaya da Costa, Felix Poppelaars, Casper F. M. Franssen, Manuel Pestana, Stefan P. Berger, Mohamed R. Daha, Mohamed R. Daha, Carlo A. J. M. Gaillard, Marc A. Seelen   +11 more
doaj   +1 more source

Intravenous iron-induced hypophosphatemia and kidney stone disease

Bone Reports
Patients with Crohn's disease are at increased risk for symptomatic nephrolithiasis. Stones in these patients are most commonly composed of calcium oxalate monohydrate or mixed calcium-oxalate and calcium-phosphate. Precipitation of both minerals depends
Marlene Panzer, Eva Meindl, Benedikt Schaefer, Sonja Wagner, Bernhard Glodny, Gert Mayer, Andreas Pircher, Christoph Schwarz, Felix Beckmann, Clivia Hejny, Bastian Joachim-Mrosko, Juergen Konzett, Herbert Tilg, Isabel Heidegger, Myles Wolf, Ralf Weiskirchen, Heinz Zoller   +16 more
doaj   +1 more source

Hypophosphatemia after high-dose iron repletion with ferric carboxymaltose and ferric derisomaltose—the randomized controlled HOMe aFers study

BMC Medicine, 2020
Background In patients with iron deficiency anemia, ferric carboxymaltose (FCM) and ferric derisomaltose (FDI) allow high-dose iron repletion. While FCM is reported to induce hypophosphatemia, the frequency of hypophosphatemia after an equivalent dosage ...
I. E. Emrich, F. Lizzi, J. D. Siegel, S. Seiler-Mussler, C. Ukena, D. Kaddu-Mulindwa, R. D’Amelio, S. Wagenpfeil, V. M. Brandenburg, M. Böhm, D. Fliser, G. H. Heine   +11 more
doaj   +1 more source

A study for efficacy and safety of ferric carboxymaltose versus iron sucrose in iron deficiency anemia among pregnant women in tertiary care hospital [PDF]

, 2019
Background: Anemia is one of the common manageable problem among the pregnant women worldwide, which contributes to maternal and perinatal mortality. This study aims to compare the efficacy and safety of intravenous ferric carboxymaltose with intravenous
Agrawal, Divyani, Masand, Deepa Lokwani
core   +1 more source

Intravenous ferric carboxymaltose versus oral ferrous sulphate for the treatment of moderate to severe postpartum anaemia in Nigerian women (IVON-PP): protocol for an open-label randomised controlled type 1 hybrid effectiveness-implementation trial

BMJ Open
Introduction Postpartum anaemia is often caused by iron deficiency with onset during the antepartum period and can be exacerbated by excessive blood loss at birth. Its prevalence is estimated as 50–80% in low-income and middle-income countries.
Mobolanle Balogun, Aduragbemi Banke-Thomas, Ejemai Amaize Eboreime, Kate Walker, Folasade Ogunsola, Eleanor J Mitchell, Bosede Bukola Afolabi, Titilope Adenike Adeyemo, Ochuwa Adiketu Babah, Victoria Olawunmi Adaramoye, Opeyemi Rebecca Akinajo, Ibraheem Ajibola Abioye, Chisom Florence Chieme, Yewande Oshodi, Rachel Quao   +14 more
doaj   +1 more source

Hypophosphatemia after intravenous iron repletion with ferric carboxymaltose and iron isomaltoside : the randomized controlled HOMe aFers study

, 2021
Inzidenz der Hypophosphatämie nach intravenöser Eisensubstitution mittels Eisen Carboxymaltose und Eisen Derisomaltose – Ergebnisse der randomisierten, kontrollierten HOMe aFers Studie Hintergrund: Bei Patienten mit Eisenmangelanämie ermöglichen Eisen ...
Siegel, Jonathan David
core   +1 more source

Update of a comparative analysis of cost minimization following the introduction of newly available intravenous iron therapies in hospital practice

Therapeutics and Clinical Risk Management, 2011
Sunil BhandariDepartment of Renal Medicine, Hull and East Yorkshire Hospitals National Health Service Trust and Hull York Medical School, Kingston upon Hull, UKBackground: The clinical need to be able to administer high doses of intravenous iron ...
Bhandari S
doaj